Physician profile
Deepak Koul
NPI 1417155672
$15,760.44
in general payments reported to CMS, 2019-2025
42 companies · $946 in 2025
The $946 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $563 · 2021: $2,918 · 2022: $4,825 · 2023: $1,920 · 2024: $2,802 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,569 · Grant: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,568.86 |
| Grant | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,939.26 | 2021-2025 | Impella |
| Abbott Laboratories | $2,437.53 | 2019-2025 | Amplatzer Amulet, Mitraclip, Aveir |
| Novartis Pharmaceuticals Corporation | $1,398.19 | 2019-2025 | |
| Boston Scientific Corporation | $1,257.24 | 2019-2024 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $734.39 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.25 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $675.32 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $604.52 | 2019-2024 | Farxiga, Brilinta |
| Edwards Lifesciences Corporation | $532.81 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal |
| Amgen INC. | $439.67 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $428.22 | 2019 | |
| Pfizer INC. | $402.59 | 2019-2024 | |
| Medtronic, INC. | $367.32 | 2021-2024 | Corevalve Evolut R |
| Sanofi-Aventis U.S. LLC | $360.12 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $344.81 | 2019-2025 | Camzyos, Eliquis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Koul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.